Orbis Research has added latest Report on “Global Companion diagnostic tests in oncology Industry 2017 Market Research Report “in their Market Research Reports store.
Companion diagnostics is synonymous with personalized, stratified, and precision medicine, and heralds a new era of treatment in which a patients’ treatment will become increasingly individualized. A companion diagnostic test is defined as an in vitro diagnostic device or imaging tool whose use allows the safe application of a therapy. In practice, this involves measuring the expression or presence of a specific biomarker that is linked to a disease condition or therapy in order to ascertain how a patient will respond to a particular treatment. A relatively narrow range of core technologies is used for companion diagnostic tests, based around the detection of nucleic acids (such as DNA) or proteins (such as cell surface receptors).
The increased demand for companion diagnostic tests is a result of the increased demand from physicians who want to be better informed of the therapy options for their patients, from regulatory authorities who are seeking the development of safer and more effective drugs, and from healthcare authorities (such as payers) who are looking to control the rising costs of therapies while being able to better identify the most suitable patients for treatment. Physicians look to stratify their patients in order to identify the most appropriate treatment, and the addition of companion diagnostic tests is seen as an extra tool in the existing prognostic process.
This report focuses on the companion diagnostic testing markets in the US, five major European markets (5EU: France, Germany, Italy, Spain, and the UK), Japan, and the future markets in China, India, and Brazil, to identify unmet needs in the global market, physician attitudes toward current companion diagnostic testing, and the future of companion diagnostic testing in the face of rapid technological advancement. The four major cancers covered in this report are breast cancer, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and melanoma.
*This is an on-demand report and will be delivered within 4 working days (excluding weekends) of the purchase.
– Overview of recent key industry events and analysis of their market impact.
– Investigation of current and future market competition in the companion diagnostics market in oncology.
– Competitive Assessment including product profiles.
– Coverage of key market players and company profiles, including business description, financial overview, product portfolio assessment, and SWOT analysis.
– Strategic Assessment of the market through market impact analysis, future market scenario, and company analysis
Reasons to buy
– Gain a high level view of the trends shaping and driving the companion diagnostics market.
– Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
– Drive revenues, formulate effective sales and marketing strategies, and gain in-depth understanding of the competitive landscape.
– Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
– Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
Agilent Technologies (Dako)
Life Technologies (Thermo Fisher Scientific)
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/240354 .
Some Points From List Of Content:
Table 1: Possible Companion Diagnostic Test Platform Technologies
Table 2: Regulatory Issues and Recalls, 2014-2016
Table 3: Mergers and Acquisitions, 2016
Table 4: Key Partnerships in 2016
Table 5: Breast Cancer Companion Diagnostic Tests, 2016
Table 6: CRC Companion Diagnostic Tests, 2016
Table 7: Melanoma Companion Diagnostic Tests, 2016
Table 8: NSCLC Companion Diagnostic Tests, 2016
Table 9: Companion Diagnostic Tests Pipeline, 2014
Table 10: Key Clinical Trials Utilizing Companion Diagnostic Tests Linked to Specific Drug Therapies
Table 11: Company Profile – Abbott Laboratories
Table 12: Abbott Laboratories Portfolio Assessment, 2016
Table 13: SWOT Analysis – Abbott Laboratories
Table 14: Company Profile – Agilent Technologies
Table 15: Agilent Technologies Portfolio Assessment, 2016
Table 16: SWOT Analysis – Agilent Technologies
Table 17: Company Profile – bioMérieux
Table 18: bioMérieux Portfolio Assessment, 2016
Table 19: SWOT Analysis – bioMérieux
Table 20: Company Profile – Illumina
Table 21: SWOT Analysis – Illumina
Table 22: Company Profile – Leica
Table 23: Leica Portfolio Assessment, 2016
Table 24: SWOT Analysis – Leica
Table 25: Company Profile – Life Technologies (Thermo Fisher Scientific)
Table 26: Life Technologies Portfolio Assessment, 2016
Table 27: SWOT Analysis – Life Technologies
Table 28: Company Profile – Qiagen
Table 29: Qiagen Portfolio Assessment, 2016
Table 30: SWOT Analysis – Qiagen
Table 31: Company Profile – Roche
Table 32: Roche Portfolio Assessment, 2016
Table 33: SWOT Analysis – Roche
Table 34: Breast Cancer Companion Diagnostic Testing Volume (thousands), 2014-2023
Table 35: CRC Companion Diagnostic Testing Volume (thousands), 2014-2023
Table 36: Melanoma Companion Diagnostic Testing Volume (thousands), 2014-2023
Table 37: NSCLC Companion Diagnostic Testing Volume (thousands), 2014-2023
Table 38: Global Cancer Companion Diagnostic Test Market Value ($m), 2014-2023
Table 39: US Cancer Companion Diagnostic Test Market Value ($m), 2014-2023
Table 40: France Cancer Companion Diagnostic Test Market Value ($m), 2014-2023
Table 41: Germany Cancer Companion Diagnostic Test Market Value ($m), 2014-2023
Table 42: Italy Cancer Companion Diagnostic Test Market Value ($m), 2014-2023
Table 43: Spain Cancer Companion Diagnostic Test Market Value ($m), 2014-2023
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/240354.